Our Mission:
Empowering the global advancement of innovative biopharmaceutical programs through science-driven strategic collaboration and international business development support.
Our Services:
Science-Driven Business Development Support:
- Scientific and strategic evaluation of innovative therapeutic assets
- International positioning and partner engagement for clinical-stage programs
- Cross-border communication and collaboration support between innovation-driven biotech companies and global pharmaceutical partners
Featured Programs & Strategic Insights:
Recent Strategic Insights:
- Post-ischemic neurovascular remodeling and recovery biology
- Treatment persistence and tolerability in IPF therapy
- Expanding opportunities in immunology and chronic inflammatory diseases
Selected Clinical-Stage Programs:
- SC1011 — Anti-fibrotic small molecule program for IPF and tissue repair applications.
- VDJ001 — Anti-IL-6R monoclonal antibody program being explored in immunology and CKD-associated anemia.
- ZHB103 — Long-acting KLK1 biologic focused on neurovascular recovery and microcirculation-related diseases.
- B1344 — Long-acting FGF21 biologic program for metabolic and MASH-related diseases.
Global Collaboration Network:
International Partnership Support
- Supporting cross-border communication and strategic collaboration involving innovative biopharmaceutical organizations across North America, Europe and Asia.
Partnered with:
Angine Biotech Co., Ltd, based in Hangzhou, China, facilitates international project transfers for the biopharmaceutical industry. They collaborate with overseas enterprises, research institutions, and investment banks, specializing in cross-border cooperation related to drugs, medical devices, and health products.
Visit their website!